Introduction
============

Colloidal nanoparticles (eg, Au and Ag) are widely used for cancer treatment in experimental oncology.[@b1-ijn-12-4257] Moreover, iron oxide nanoparticles, measuring 5--20 nm, have become extremely popular in various industrial, laboratory, and biomedical applications, including diagnostics and treatment.[@b2-ijn-12-4257] In particular, magnetic targeting is a very attractive strategy that is used to deliver particles and fix them to the desired target area using a magnetic field. Magnetic nanoparticles, thus, serve in drug delivery systems, cell labeling, and as contrast agents in MRI. Various beneficial effects of certain nanoparticles on cancer treatment have also been described.[@b3-ijn-12-4257],[@b4-ijn-12-4257] Iron oxide nanoparticles -- namely, maghemite (γ-Fe~2~O~3~) or magnetite (Fe~3~O~4~) -- are advantageous because their biocompatibility has already been demonstrated.[@b5-ijn-12-4257] Another benefit of iron oxide nanoparticles is their superparamagnetic behavior, as they do not retain any magnetism after removal from the magnetic field, but they are attracted to a magnet. Superparamagnetic particles have dimensions smaller than a particular magnetic domain.[@b6-ijn-12-4257] Their main advantages are manipulability, targetability by a magnet, easy magnetic separation, and monitoring by MRI.

Many chemical approaches, such as coprecipitation, sol-gel, microemulsion, sonochemical, hydrothermal, and solvo-thermal methods, as well as electrochemical deposition under oxidized conditions, thermal decomposition, and biomimetic synthesis have been used to prepare superparamagnetic iron oxide nanoparticles.[@b7-ijn-12-4257] Other reports have described surface reactions on magnetic nanoparticles that can be performed either during synthesis or by a post-synthesis modification. Among coating methods, atom-transfer radical polymerization has a special role.[@b8-ijn-12-4257] Coating should ensure colloidal stability of the particles in aqueous media, inhibit undesirable protein adsorption, and allow binding to drugs or other target biomolecules. Coatings of silica,[@b9-ijn-12-4257] poly(ethylene glycol),[@b10-ijn-12-4257] poly(vinyl alcohol),[@b11-ijn-12-4257] polyvinylpyrrolidone,[@b12-ijn-12-4257] poly(acrylic acid),[@b13-ijn-12-4257] poly(methyl methacrylate),[@b14-ijn-12-4257] chitosan,[@b15-ijn-12-4257] dextran,[@b16-ijn-12-4257] starch,[@b17-ijn-12-4257] ethyl cellulose,[@b18-ijn-12-4257] albumin,[@b19-ijn-12-4257] and gelatin[@b20-ijn-12-4257] have been described.

Vitamin E (α-tocopherol) is well-known for its strong affinity to biomembranes due to its interactions with phospholipids; however, it lacks antitumor, as well as anti-metastatic, activity. By contrast, synthesized short-chain vitamin E analogs exhibit excellent anticancer activity[@b21-ijn-12-4257] and are, therefore, recommended for prophylaxis and cancer treatment. One disadvantage of α-tocopherol (Toc) is its lipophilicity, which is associated with difficulties in preparing environment-friendly aqueous dispersions.[@b22-ijn-12-4257],[@b23-ijn-12-4257] This lipophilicity can be overcome by encapsulating Toc into suitable polymers[@b24-ijn-12-4257] or using biocompatible surfactants[@b25-ijn-12-4257] or water-soluble vitamin E derivatives.[@b26-ijn-12-4257] *D*-α-tocopheryl poly(ethylene glycol) succinate (vitamin E TPGS NF) is commercially available from Eastman[@b27-ijn-12-4257] and is used as an emulsifier, surfactant, drug solubilizer, absorption enhancer, and vehicle for lipid-based drug delivery formulations. For example, vitamin E TPGS NF-coated magnetic polylactide and polyglycolide nanoparticles are suitable for multimodal MRI and fluorescence imaging.[@b28-ijn-12-4257] An aqueous dispersion of magnetic particles coated with another water-soluble low-molecular-weight derivative of vitamin E called Trolox (6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid) was tested as a radical scavenger.[@b29-ijn-12-4257]

Despite extensive investigations on magnetic nanoparticles, their redox capacity and anticancer activity are still not fully understood. Here, we describe the preparation of novel surface-modified iron oxide nanoparticles and demonstrate their in vitro Fe^2+^ release and antitumor activity, which are synergistically increased by the addition of the phenolic derivative of Toc (Toc-6-OH). The biological activity of these nanoparticles is compared with that of commercially available magnetic nanoparticles exemplified by CuFe~2~O~4~. This work is a continuation of our previous reports on the use of poly(*N,N*-dimethylacrylamide) (PDMA)-coated maghemite nanoparticles for stem cell and macrophage labeling.[@b30-ijn-12-4257],[@b31-ijn-12-4257]

Methods
=======

Materials
---------

FeCl~2~·4 H~2~O, FeCl~3~·6 H~2~O, *N,N*-dimethylacrylamide (DMA), 4,4′-azobis(4-cyanovaleric acid) (ACVA), NaCl, Tris, thiobarbituric acid (TBA), trichloroacetic acid, copper iron oxide (CuFe~2~O~4~), 1,10-phenanthroline, Toc, and cell culture medium 199 were obtained from Sigma-Aldrich (St Louis, MO, USA). The Toc derivative with an isoprenoid side chain shortened to 6 carbon atoms ([Figure 1](#f1-ijn-12-4257){ref-type="fig"}) was synthesized both in its phenolic (Toc-6-OH) and acetate forms (Toc-6-Ac) according to a method described previously.[@b21-ijn-12-4257] Doxorubicin was obtained from Arterium (Kiev, Ukraine), and a sodium hypochlorite solution was obtained from Bochemie (Bohumín, Czech Republic). Other reagents and solvents were purchased from LachNer (Neratovice, Czech Republic). Ultrapure Q water, ultrafiltered in a Milli-Q Gradient A10 system (Millipore; Molsheim, France), was used to prepare solutions.

Preparation of poly(*N,N*-dimethylacrylamide)-modified γ-Fe~2~O~3~ nanoparticles
--------------------------------------------------------------------------------

γ-Fe~2~O~3~ was prepared from FeCl~3~, FeCl~2~ (2:1, mol/mol), and NH~4~OH, followed by oxidation with sodium hypochlorite.[@b32-ijn-12-4257] Uncoated γ-Fe~2~O~3~ served both as a control in animal experiments and as a starting material for the preparation of polymer-modified particles. To prepare poly(*N,N*-dimethylacrylamide), both DMA (3 g) and ACVA (10 mg) were dissolved in a toluene/tetrahydrofuran (THF) mixture (3.5:3.4 mL/mL) and polymerization was initiated by heating at 70°C for 8 h with magnetic stirring. The resulting PDMA was precipitated into diethyl ether and vacuum-dried at room temperature (RT). An aqueous PDMA (8.8 mg/mL) solution (5 mL) was then added to the γ-Fe~2~O~3~ ferrofluid (5 mL; 8.8 mg γ-Fe~2~O~3~/mL), yielding γ-Fe~2~O~3~\@PDMA nanoparticles.

Physicochemical characterization
--------------------------------

Both particle size and particle size distribution were determined from transmission electron micrographs (TEM) using an FEI Tecnai Spirit G^2^ microscope (Brno, Czech Republic). The number-average diameters (*D*~n~ = ∑*D*~i~/N), weight-average diameters $(D_{w} = \sum D_{i}^{4}/\sum D_{i}^{3})$, and polydispersity indexes (PDI = *D*~w~/*D*~n~) were calculated from \~500 particles using Atlas software (Tescan Digital Microscopy Imaging; Brno, Czech Republic), where N is the number of particles. The effect of 0.1 M HCl (1 mL, pH 3) on the degradation of γ-Fe~2~O~3~\@PDMA nanoparticles (13.2 µg) was determined in 1.5-mL Eppendorf tubes after 1-h treatment at 37°C with shaking (200 rpm). The hydrodynamic diameter *D*~h~, poly-dispersity PI, and ζ-potential were measured by dynamic light scattering (DLS) with a Malvern Instruments Autosizer Lo-C (Malvern, UK). Elemental analysis was performed on a PerkinElmer 2400 CHN apparatus (Norwalk, CT, USA). The molecular weight of PDMA was determined by size-exclusion chromatography (SEC) on a gradient Knauer system (Berlin, Germany) with detection using diode array and Alltech 3300 evaporative light scattering. A Phenomenex PolySept-GFC-P linear column (Torrance, CA, USA) was used in isocratic 0.03 M ammonium acetate buffer in CH~3~CN/water (20:80, v/v). Infrared spectra were measured on a Perkin Elmer PARAGON 1000 PC Fourier transform infrared (FTIR) spectrometer equipped with a Specac MKII Golden Gate Single Reflection ATR System with diamond crystals. Magnetic properties were measured on a SQUID MPMS5 magnetometer (Quantum Design; San Diego, USA) at 300 K. The relative content of polymer and γ-Fe~2~O~3~ was determined using a Perkin Elmer TGA 7 thermogravimetric analyzer (Norwalk, CT, USA). Particles were heated from RT to 800°C at a heating rate of 10°C/min.

Determination of Fe^2+^ release from the nanoparticles
------------------------------------------------------

The concentration of Fe^2+^ released from iron oxide nanoparticles was determined using a colorimetric method with a Fe^2+^-1,10-phenanthroline complex by measuring absorbance at 510 nm on an MQX 200 BioTek UV spectrophotometer (Winooski, VT, USA).[@b32-ijn-12-4257] The reaction mixture contained a 0.25-mg nanoparticles/mL, 0.005 wt.% of 1,10-phenanthro-line solution in ethanol (added before incubation to bind the released Fe^2+^ and to prevent its oxidation to Fe^3+^) and Toc or Toc-6-OH at concentrations ranging from 100 to 1,000 µM. The reactions were run in 0.9% NaCl solution and 10 mM Tris (pH 7.4) at 37°C for 24 h with shaking (200 rpm). The nanoparticles were then separated by centrifugation at 1,500 *g* for 15 min, and the absorbance of the colored complex, which is directly proportional to the Fe^2+^ concentration, was analyzed in the supernatant. Fe^2+^ release from the nanoparticles in the absence of Tocs served as a control.

Preparation of blood serum
--------------------------

Blood serum was obtained from Wistar rats weighing 250--300 g. Immediately after euthanasia, blood (\~5 mL) was taken by heart puncture with a syringe and transferred into a centrifuge tube that was left to stand at RT for 30 min. Blood was then separated by centrifugation at 1,500 *g* for 15 min, and serum was stored in polystyrene tubes at −80°C before blood lipid oxidation tests.

Preparation of whole blood and blood plasma and determination of liver enzymatic activities
-------------------------------------------------------------------------------------------

Blood (\~5 mL) taken by the above procedure was transferred into a Li-heparin blood collection tube (Vacutest Kima; Arzergande, Italy). The tube was inverted twice and blood cells were counted in a PCE210 hematology particle counter (Erma; Tokyo, Japan). The remainder of the blood was centrifuged at 1,500 *g* for 15 min to separate cells from the plasma. Bilirubin[@b33-ijn-12-4257] and activities of alanine aminotransferase (ALT)[@b34-ijn-12-4257] and aspartate aminotransferase (AST)[@b35-ijn-12-4257] were determined using a biochemistry and immunochemistry analyzer 2990 (Global Biomarketing Group; Palo Alto, CA, USA).

Blood lipid oxidation
---------------------

Lipid oxidation was determined by measuring 2-thiobarbituric acid reactive species (TBARS).[@b36-ijn-12-4257] Nanoparticles were incubated with blood serum (25 µL) in 0.9% NaCl and 10 mM Tris (pH 7.4) at 37°C for 24 h with shaking (200 rpm). After incubation, 0.375% TBA, 15% trichloroacetic acid, and 0.25 M HCl were added, and the mixture was heated at 95°C for 30 min. Protein pellets were separated from the supernatant by centrifugation at 3,000 *g* for 15 min. Aliquots of the supernatant (200 µL) were analyzed on an MQX 200 BioTek spectrophotometer (Winooski, VT, USA) at 540 nm. Malondialdehyde standards were used for TBARS calibration, and neat serum served as a control.

Antitumor activity
------------------

Walker-256 carcinosarcoma (W-256) female Wistar rats weighing 150 g served as an in vivo mammary gland tumor model. For tumor inoculation, a suspension of 23% W-256 tumor tissue in cell culture medium 199 (0.4 mL) was subcutaneously injected into the back of each animal. Animals were divided into the following groups: 1) without any treatment (except saline), which served as a control; or treated with 2) doxorubicin (1.5 mg/kg), typically on day 3 after W-256 transplantation when tumor size reached 7--10 mm and 3) Toc-6-Ac, 4) CuFe~2~O~4~, 5) γ-Fe~2~O~3~, 6) γ-Fe~2~O~3~@ PDMA, 7) CuFe~2~O~4~ and Toc-6-Ac, 8) γ-Fe~2~O~3~ and Toc-6-Ac, or 9) γ-Fe~2~O~3~\@PDMA and Toc-6-Ac. With the exception of 2), where doxorubicin was administered intraperitoneally due to its poor bioavailability after the oral administration,[@b37-ijn-12-4257] the other agents (25 mg of Toc-6-Ac and 10 mg of the nano-particles per kg) were administered per os into the stomach in all of the other experiments. Each group consisted of five to seven animals. Animals received five injections of doxorubicin, CuFe~2~O~4~, γ-Fe~2~O~3~, or γ-Fe~2~O~3~\@PDMA nano-particles; or 10 injections of Toc-6-Ac for 10 days. At the end of the experiment, the tumor size was measured with a caliper, and tumor volume (V) was calculated using the following formula:[@b38-ijn-12-4257] $$V = \left( {4/3} \right) \times \pi \times (L/2) \times (W/2) \times (D/2)/1000$$,where *L*, *W*, and *D* represent the tumor length, width, and depth (mm), respectively. The mean tumor volume was calculated in cm^3^, and the SE for each group was determined.

Ethical issues of animal use
----------------------------

Experiments conducted on non-transgenic Wistar female rats were performed according to European Commission regulations and were approved by the ethical committees of the Palladin Institute of Biochemistry and the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology. Rats were kept in a special facility and euthanized through carbon dioxide asphyxiation before necropsy.[@b39-ijn-12-4257],[@b40-ijn-12-4257]

Statistical analysis
--------------------

Two-tailed Student's *t*-test was used for comparisons between experimental groups. The level of significance was set at *P*\<0.05. All data are presented as the mean ± SE.

Results and discussion
======================

Superparamagnetic γ-Fe~2~O~3~ nanoparticles
-------------------------------------------

In the present work, superparamagnetic iron oxide nanoparticles were synthesized by coprecipitation using ammonium hydroxide as the precipitation agent.[@b41-ijn-12-4257] The resulting Fe~3~O~4~ nanoparticles were oxidized to γ-Fe~2~O~3~, which is preferred to Fe~3~O~4~ due to its resistance to uncontrolled oxidation that often results in non-magnetic products. Superparamagnetic iron oxides can be magnetized in an external magnetic field. However, in its absence, magnetization disappears and the particles become dispersible in water. The surface of the γ-Fe~2~O~3~ nanoparticles must be modified to make them both colloidally stable in aqueous media and to enable penetration of the nanoparticles into cells. PDMA was selected as the nanoparticle coating due to its hydrophilicity, excellent biocompatibility, and minimal non-specific protein adsorption.[@b42-ijn-12-4257] PDMA was obtained by ACVA-initiated polymerization of DMA in a toluene/THF solution. One advantage of ACVA is the presence of carboxyl groups, which form complexes with Fe ions, thus facilitating attachment of the polymerization initiator to the surface of iron oxide.[@b43-ijn-12-4257] The carboxyl groups of ACVA also offer the possibility of the attachment of anticancer drugs containing OH and/or NH~2~ groups, such as etoposide, doxorubicin, genistein, and topotecan, for targeted drug delivery.[@b44-ijn-12-4257] According to the elemental analysis, PDMA contained 59.5, 13.6, and 10.1 wt.% of C, N, and H, respectively. The rather small discrepancy in the calculated values (C 60.6, N 14.1, and H 9.2 wt.%) may be caused by the presence of residual water in the polymer. According to SEC, the molecular weight of PDMA was \~50,000 Da, with a relatively broad distribution caused by chain-transfer reactions with the solvent (THF). It should be noted that such a molecular weight does not exceed the renal threshold.[@b45-ijn-12-4257] According to TEM ([Figure 2A and B](#f2-ijn-12-4257){ref-type="fig"}), the size of uncoated and coated nanoparticles was similar (12 nm). In addition, the PDI (1.12) remained unchanged and rather low, indicating the absence of undesirable aggregation. For comparison purposes, the size of commercial CuFe~2~O~4~ nanoparticles was relatively large (40 nm) with a very broad particle size distribution (PDI =1.42; [Figure 2D](#f2-ijn-12-4257){ref-type="fig"}). As the pH in the gastrointestinal tract of mammals is an important factor affecting the stability and solubility of drugs, food, and its supplements, the effect of 0.1 M HCl, which mimics the stomach environment (pH 3),[@b46-ijn-12-4257] on the dissolution of nanoparticles was investigated. It was determined that 0.1 M HCl did not degrade γ-Fe~2~O~3~\@PDMA particles ([Figure 2C](#f2-ijn-12-4257){ref-type="fig"}).

DLS measurements revealed that the hydrodynamic diameter of starting γ-Fe~2~O~3~ was larger (*D*~h~ =54 nm) than the number-average diameter (*D*~n~) from TEM, and the polydispersity PI of 0.14 roughly corresponded with PDI (according to TEM). Compared to neat γ-Fe~2~O~3~, both the hydrodynamic diameter (*D*~h~ =72 nm) and polydispersity (PI =0.19) of the γ-Fe~2~O~3~\@PDMA nanoparticles were slightly larger due to the polymer coating. It should be noted that the polydispersity PI, according to DLS, differed substantially from the polydispersity index PDI according to TEM, where a PDI of 1 represents monodispersed particles, whereas polydispersed particles typically exhibit PDIs \>1.05. DLS always yields a larger particle size compared to TEM due to principal differences in both measurements and the statistical treatment. It should also be noted that, whereas the former method measures particles in water, the latter measures particles in the dry state. High absolute values of the ζ-potential of both coated (−35.8 mV) and uncoated (−44 mV) γ-Fe~2~O~3~ particles indicated good colloidal stability. As subtle change in pH, which decreased from 10.17 (γ-Fe~2~O~3~) to 9.92 (γ-Fe~2~O~3~@ PDMA), was induced by the COOH groups in PDMA originating from ACVA initiation.

[Figure 3A](#f3-ijn-12-4257){ref-type="fig"} shows the attenuated total reflection (ATR) FTIR spectra of pure PDMA and PDMA-coated and uncoated γ-Fe~2~O~3~ nanoparticles. The spectra of pure PDMA and γ-Fe~2~O~3~\@PDMA nanoparticles were identical, which can be attributed to the high amount of polymer relative to iron oxide (1:1, w/w). Amide bands were observed at 1,614 and 1,402 cm^−1^. The peaks at 1,498 and 1,354 cm^−1^ were ascribed to the CH~3~ deformation vibration.

According to TGA analysis, a slight decrease in weight with heating was caused by the evaporation of water bound to γ-Fe~2~O~3~ ([Figure 3B](#f3-ijn-12-4257){ref-type="fig"}). By contrast, γ-Fe~2~O~3~\@PDMA particles lost a substantial amount of weight (\~40 wt.%) during heating from 280°C to 400°C, which roughly corresponded to the amount of polymer added in the reaction mixture during surface modification.

The superparamagnetic properties of γ-Fe~2~O~3~, γ-Fe~2~O~3~@ PDMA, and CuFe~2~O~4~ nanoparticles were confirmed on a SQUID magnetometer, as no hysteresis loops were observed ([Figure 3C](#f3-ijn-12-4257){ref-type="fig"}). The remanent magnetizations and coercivities were also low -- amounting to 1.37 A·m^2^·kg^−1^ and 1.69 kA·m^−1^, respectively, for neat γ-Fe~2~O~3~, and 0.93 A·m^2^∙kg^−1^ and 1.28 kA·m^−1^, respectively, for γ-Fe~2~O~3~@ PDMA particles. The saturation, remanent magnetization, and coercivity values of the CuFe~2~O~4~ particles were 21.16, 0.22 A·m^2^·kg^−1^, and 0.35 kA·m^−1^, respectively, which were lower than those of γ-Fe~2~O~3~. A lower saturation magnetization of γ-Fe O 2 2 3 (53 A·m ·kg^−1^) relative to that of bulk γ-Fe~2~O~3~ (60--80 A·m^2^·kg^−1^)[@b5-ijn-12-4257] indicated the presence of impurities and/or water, which was confirmed by FTIR spectroscopy and TGA. The saturation magnetization of the γ-Fe~2~O~3~@ PDMA nanoparticles was 26.1 A·m^2^·kg^−1^, suggesting that the composite particles contained 49 wt.% of PDMA, roughly corresponding to the amount of polymer coating determined by TGA.

Fe^2+^ release
--------------

In vitro Fe^2+^ release from CuFe~2~O~4~, γ-Fe~2~O~3~, and γ-Fe~2~O~3~@ PDMA nanoparticles is shown in [Figure 4](#f4-ijn-12-4257){ref-type="fig"}. The presence of Toc-6-OH in the incubation medium induced a higher amount of Fe^2+^ released from the nanoparticles compared to that with the same amount of Toc. The amount of Fe^2+^ released from CuFe~2~O~4~ nanoparticles ([Figure 4A](#f4-ijn-12-4257){ref-type="fig"}) was lower compared to that released from γ-Fe~2~O~3~ and γ-Fe~2~O~3~@ PDMA particles ([Figure 4B and C](#f4-ijn-12-4257){ref-type="fig"}), which is likely due to the presence of Cu^2+^ ions on the CuFe~2~O~4~ particle surface. With \~470 µmol of Toc-6-OH in the incubation medium, \~50 and 25 µmol of Fe^2+^ was released from γ-Fe~2~O~3~\@PDMA and neat γ-Fe~2~O~3~ nanoparticles, respectively ([Figure 4B and C](#f4-ijn-12-4257){ref-type="fig"}). It can be speculated that Toc-6-OH was more accessible to the particle surface due to its shorter side chain, compared to highly hydrophobic Toc. Therefore, penetration of Toc-6-OH through the PDMA coating to the particle core was facilitated. Another possible effect influencing Fe^2+^ release from the particles is the higher redox activity of Toc-6-OH compared to that of Toc. The release of Fe^2+^ from the particles can be ascribed to a reduction of Fe^3+^ ions to Fe^2+^; this well-known reaction is used for Toc determination.[@b47-ijn-12-4257] The greater Fe^2+^ release from the γ-Fe~2~O~3~\@PDMA compared to that from the γ-Fe~2~O~3~ particles can be ascribed to the ability of the amide PDMA bond to form complexes with surface Fe^3+^ ions of maghemite, which increases its solubility product constant and induces release of Fe^3+^ in the solution, where Fe^3+^ is reduced to Fe^2+^.

Biological experiments
----------------------

As Fe^2+^ accelerates lipid peroxidation,[@b36-ijn-12-4257],[@b48-ijn-12-4257] the effects of CuFe~2~O~4~, γ-Fe~2~O~3~, and γ-Fe~2~O~3~\@PDMA nanoparticles on lipid oxidation in blood serum were investigated in vitro ([Figure 5](#f5-ijn-12-4257){ref-type="fig"}). Lipid peroxidation increased with increasing concentration of the particles in the blood serum; it decreased in the following order: CuFe~2~O~4~ \> γ-Fe~2~O~3~ \~ γ-Fe~2~O~3~\@PDMA. Among the tested particles, the strongest effect of CuFe~2~O~4~ on lipid oxidation can be ascribed to the presence of Cu^2+^ ions,[@b34-ijn-12-4257] which better initiate peroxidation than Fe^3+^ ions.[@b48-ijn-12-4257]

As the biological activity of vitamin E is closely related to its free hydroxyl groups, Toc-6-OH was selected for subsequent in vivo experiments. To increase the long-term storage stability of Toc, its acetate derivative (Toc-6-Ac) was used, because Toc-6-Ac is believed to behave similarly to vitamin E acetate, which undergoes hydrolysis in the living organism, forming the biologically active hydroxyl form of vitamin E.[@b49-ijn-12-4257],[@b50-ijn-12-4257]

To investigate the effect of orally administered iron oxide nanoparticles (CuFe~2~O~4~, γ-Fe~2~O~3~, γ-Fe~2~O~3~\@PDMA, optionally in combination with Toc-6-Ac) on tumor growth, in vivo experiments on Wistar rats with W-256 carcinosarcoma were performed ([Figure 6](#f6-ijn-12-4257){ref-type="fig"}). The tumor volume was smaller in γ-Fe~2~O~3~\@PDMA-treated rats compared to that in animals administered CuFe~2~O~4~ or γ-Fe~2~O~3~ particles ([Figure 7](#f7-ijn-12-4257){ref-type="fig"}, nanoparticles no 4--6). Administration of Toc-6-Ac to tumor-bearing rats decreased the tumor volume by 40% -- that is, to the same extent as the clinically used anticancer drug doxorubicin. By contrast, γ-Fe~2~O~3~\@PDMA nanoparticles exhibited significantly stronger antitumor activity, decreasing the tumor volume by 60%, which was consistent with previous data.[@b51-ijn-12-4257] Combined administration of nanoparticles with Toc-6-Ac decreased the tumor size to an even greater extent, and the resulting antitumor activity was significantly higher than that of doxorubicin. It can thus be hypothesized that this strong in vivo antitumor effect was induced by the nanoparticle redox activity associated with increased Fe^2+^ release from the particles in the presence of Toc-6-Ac, as previously shown in vitro ([Figure 4](#f4-ijn-12-4257){ref-type="fig"}). Iron plays an important role in tumor development[@b52-ijn-12-4257] and cancer treatment,[@b53-ijn-12-4257],[@b54-ijn-12-4257] and iron oxide nanoparticles induce dose-dependent cytotoxicity and generate oxidative stress by increasing the production of superoxide anions and nitric oxide in human umbilical endothelial cells.[@b55-ijn-12-4257] At high doses, iron oxide nanoparticles dissolve in the cytosol, and Fe ions may affect intracellular reactive oxygen species homeostasis via the Fenton reaction,[@b56-ijn-12-4257] thus generating oxidative stress to induce cell toxicity.[@b57-ijn-12-4257],[@b58-ijn-12-4257] By contrast, lipid peroxidation does not appear to play a significant role in the antitumor activity of the particles ([Figure 5](#f5-ijn-12-4257){ref-type="fig"}). The highest amount of lipid peroxidation was observed for CuFe~2~O~4~ particles, which exhibited the lowest antitumor activity compared to γ-Fe~2~O~3~ and γ-Fe~2~O~3~@ PDMA particles.

When considering the mechanism of the antitumor effect of γ-Fe~2~O~3~\@PDMA nanoparticles, it is important to note that the particle dispersion has to first pass through the stomach, as described in an earlier report.[@b59-ijn-12-4257] Here, we proved that a highly acidic medium that mimicked the stomach conditions did not damage γ-Fe~2~O~3~\@PDMA particles due to the protective PDMA shell. The particles could then enter the gastrointestinal tract and blood circulation system to reach organs such as the liver, kidney, and mesentery.[@b60-ijn-12-4257] To be resorbed into the blood stream, we speculate that the particles penetrated the mucus barrier of the small intestine due to their small size, which allowed secretion by the epithelium. It is also important to note that the bioaccumulation of iron oxide nanoparticles after oral treatment, which is the most common and natural way of drug delivery, has not yet been described.[@b61-ijn-12-4257] Nevertheless, it is known that particles circulating in the bloodstream are preferentially accumulated by tumor cells due to their increased proliferative activity and passive transfer, which is known as the enhanced permeability and retention (EPR) effect.[@b62-ijn-12-4257] Differences in cellular uptake between cancer cells and normal cells have been observed by many authors,[@b63-ijn-12-4257] although the reasons for these differences are still under investigation. Several studies suggest that this difference may be related to the difference in the endocytosis pathways between normal cells and cancer cells.[@b64-ijn-12-4257],[@b65-ijn-12-4257] Within tumor cells, cytotoxic Fe^2+^ is released under the formation of a singlet oxygen, leading to cell membrane and mitochondrial damage.[@b66-ijn-12-4257]

To further determine the cytotoxicity of CuFe~2~O~4~, γ-Fe~2~O~3~, and γ-Fe~2~O~3~\@PDMA nanoparticles (including their combination with Toc-6-Ac) administered to tumor-bearing animals, hepatic indicators (ALT, AST, and bilirubin content) were measured in blood plasma ([Figure 8](#f8-ijn-12-4257){ref-type="fig"}). Compared to control tumor-bearing rats, ALT activity in all groups of treated animals decreased, ultimately reaching the levels in intact control animals ([Figure 8A](#f8-ijn-12-4257){ref-type="fig"}). By contrast, AST activity was only decreased in animals administered nanoparticles and Toc-6-Ac, reaching the levels of intact control rats ([Figure 8B](#f8-ijn-12-4257){ref-type="fig"}). The bilirubin content in the blood plasma of animals treated with the particles was significantly lower compared to that in tumor-bearing rats ([Figure 8C](#f8-ijn-12-4257){ref-type="fig"}), indicating intensified iron metabolism in the liver of treated -- compared to untreated -- animals. Combined administration of the nanoparticles with Toc-6-Ac increased the bilirubin content to the level in intact control animals. These results, thus, demonstrate that the developed nanoparticles orally administered in Wistar rats with Walker-256 carcinosarcoma do not induce toxicity in the liver, which is a dominant organ of nanoparticle accumulation.

To investigate the cytotoxicity of the nanoparticles on white and red blood cells of tumor-bearing rats, hematologic studies were performed. While CuFe~2~O~4~ administration significantly increased the white blood cell counts, likely due to acute inflammation ([Figure 9A](#f9-ijn-12-4257){ref-type="fig"}), other nanoparticles -- both neat and in combination with Toc-6-Ac -- did not significantly affect this count. By contrast, administration of toxic doxorubicin decreased the white blood cell count ([Figure 9A](#f9-ijn-12-4257){ref-type="fig"}). No marked changes in the red blood cell count were found in tumor-bearing rats after administration of doxorubicin, Toc-6-Ac, CuFe~2~O~4~, γ-Fe~2~O~3~, γ-Fe~2~O~3~\@PDMA, or their combination with Toc-6-Ac ([Figure 9B](#f9-ijn-12-4257){ref-type="fig"}).

Conclusion
==========

In the present work, alkaline coprecipitation of FeCl~2~ and FeCl~3~ aqueous solutions followed by oxidation with NaOCl produced \~10 nm superparamagnetic γ-Fe~2~O~3~ nanoparticles with a relatively narrow particle size distribution. Subsequently, PDMA was synthesized and used as a coating to improve the colloidal stability of the nanoparticles. Iron oxide nanoparticles are advantageous in that they are not only biocompatible and easily and noninvasively monitored by MRI[@b67-ijn-12-4257] but they can also be simply targeted to a tumor via a magnet. Colorimetric analysis of the γ-Fe~2~O~3~\@PDMA nanoparticles confirmed the in vitro release of Fe^2+^ from the particles that was enhanced in the presence of Toc-6-OH. Thus, we conclude that Fe^2+^ plays a crucial role in initiating lipid oxidation, as shown by the enhanced blood lipid oxidation in the presence of the tested nanoparticles in vitro. Of the tested particles, CuFe~2~O~4~ oxidized lipids most efficiently.

In vivo, oral administration of Toc-6-Ac to Wistar rats with model Walker-256 mammary gland carcinosarcoma induced similar antitumor effects as those of doxorubicin. The antitumor activity of γ-Fe~2~O~3~\@PDMA nanoparticles was significantly higher than that of doxorubicin. The beneficial effect of Fe^2+^ release from the particles and Toc-6-Ac antitumor activity were, thus, confirmed in vivo and their combined activities documented. It should be noted that, compared to highly toxic compounds, such as doxorubicin, the γ-Fe~2~O~3~\@PDMA particles are advantageous in the absence of systemic toxicity. To further monitor the biological effects of both γ-Fe~2~O~3~\@PDMA and Toc-6-Ac in vivo, ALT and AST enzyme activities were analyzed in the blood plasma of Wistar rats with Walker-256 carcinosarcoma that were treated as described earlier. All of the investigated compounds and their combinations decreased ALT activity in tumor-bearing rats, reaching baseline levels in intact control animals, suggesting the absence of liver dysfunction. In other words, the non-toxicity of the newly developed preparations was confirmed. AST activity decreased only in rats after receiving combined oral administration of the nanoparticles and Toc-6-Ac. This finding was in agreement with blood tests in the presence of γ-Fe~2~O~3~\@PDMA particles and Toc-6-Ac, wherein bilirubin levels did not differ from those of intact control animals. Moreover, the white and red blood counts were not affected by administration of γ-Fe~2~O~3~\@PDMA, Toc-6-Ac, or both. We, thus, conclude that these promising results can be prospectively employed for the design of a new cancer treatment using the combined administration of γ-Fe~2~O~3~\@PDMA nanoparticles and Toc-6-Ac.
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![α-Tocopherol derivative with an isoprenoid side chain shortened to 6 carbon atoms in (**A**) phenolic and (**B**) acetate forms.](ijn-12-4257Fig1){#f1-ijn-12-4257}

![Transmission electron micrographs of (**A**) γ-Fe~2~O~3~ and (**B**) γ-Fe~2~O~3~\@PDMA nanoparticles before and (**C**) after incubation in 0.1 M HCl (pH 3) at 37°C for 1 h, and (**D**) CuFe~2~O~4~ nanoparticles.](ijn-12-4257Fig2){#f2-ijn-12-4257}

![(**A**) FTIR spectra of (1) PDMA, (2) γ-Fe~2~O~3~\@PDMA, and (3) γ-Fe~2~O~3~ nanoparticles. (**B**) TGA of (1) γ-Fe~2~O~3~ and (2) γ-Fe~2~O~3~\@PDMA nanoparticles. (**C**) SQUID measurements of (1) γ-Fe~2~O~3~, (2) γ-Fe~2~O~3~\@PDMA, and (3) CuFe~2~O~4~ nanoparticles.\
**Abbreviations:** TGA, thermogravimetric analysis; SQUID, superconducting quantum interference device; PDMA, poly(*N*,*N*-dimethylacrylamide); FTIR, Fourier transform infrared.](ijn-12-4257Fig3){#f3-ijn-12-4257}

![In vitro Fe^2+^ release from (**A**) CuFe~2~O~4~, (**B**) γ-Fe~2~O~3~, and (**C**) γ-Fe~2~O~3~\@PDMA nanoparticles in the presence of different concentrations of (♦) Toc and (■) Toc-6-OH. Nanoparticles (250 µg/mL) were incubated in a 0.9% NaCl solution and 10 mM Tris (pH 7.4) at 37°C for 24 h. Data are presented as the mean ± SE (n=5--8). \*Significantly different from the absence of Toc and Toc-6-OH. ^\#^Significantly different from Toc.](ijn-12-4257Fig4){#f4-ijn-12-4257}

![In vitro lipid oxidation in the blood serum in the (1) absence or (2--4) presence of CuFe~2~O~4~, (5--7) γ-Fe~2~O~3~, and (8--10) γ-Fe~2~O~3~\@PDMA nanoparticles incubated at 37°C for 24 h; (2, 5, 8) 4.4, (3, 6, 9) 44, and (4, 7, 10) 444 µg of particles per milliliter. Data are presented as the mean ± SE (*n*=5--8). \*Significantly different from (1).\
**Abbreviations:** TBARS, thiobarbituric acid reactive species; PDMA, poly(*N*,*N*-dimethylacrylamide).](ijn-12-4257Fig5){#f5-ijn-12-4257}

![Antitumor effect of γ-Fe~2~O~3~\@PDMA nanoparticles on Walker-256 mammary gland carcinosarcoma in Wistar rats. From left to right: untreated rat with a tumor (control), rat with a tumor treated with intraperitoneally administered doxorubicin, and rat with a tumor treated with γ-Fe~2~O~3~\@PDMA nanoparticles administered per os.\
**Abbreviation:** PDMA, poly(*N*,*N*-dimethylacrylamide).](ijn-12-4257Fig6){#f6-ijn-12-4257}

![In vivo antitumor activity of nanoparticles on Walker-256 mammary gland carcinosarcoma in Wistar rats. (1) No treatment (control), treatment with (2) 1.5 mg of doxorubicin, (3) 25 mg of Toc-6-Ac, (4) 10 mg of CuFe~2~O~4~, (5) 10 mg of γ-Fe~2~O~3~, (6) 10 mg of γ-Fe~2~O~3~\@PDMA, (7) 10 mg of CuFe~2~O~4~ + 25 mg of Toc-6-Ac, (8) 10 mg of γ-Fe~2~O~3~ + 25 mg of Toc-6-Ac, or (9) 10 mg of γ-Fe~2~O~3~\@PDMA + 25 mg of Toc-6-Ac per kilogram of body weight. Data are presented as the mean ± SE (*n*=5--7). \*Significantly different from (1) control animals; ^\#^significantly different from 2) animals treated with doxorubicin.\
**Abbreviation:** PDMA, poly(*N*,*N*-dimethylacrylamide).](ijn-12-4257Fig7){#f7-ijn-12-4257}

![In vivo determination of hepatic function using (**A**) ALT, (**B**) AST, and (**C**) bilirubin analyses of the blood plasma of Wistar rats with Walker-256 mammary gland carcinosarcoma. (1) No treatment (tumor control), treatment with (2) 1.5 mg of doxorubicin, (3) 25 mg of Toc-6-Ac, (4) 10 mg of CuFe~2~O~4~, (5) 10 mg of γ-Fe~2~O~3~, (6) 10 mg of γ-Fe~2~O~3~\@PDMA, (7) 10 mg of CuFe~2~O~4~ + 25 mg of Toc-6-Ac, (8) 10 mg of γ-Fe~2~O~3~ + 25 mg of Toc-6-Ac, or (9) 10 mg of γ-Fe~2~O~3~\@PDMA + 25 mg of Toc-6-Ac kilogram of body weight, and (10) non-treated rats without a tumor (intact control). Data are presented as the mean ± SE (n=5--7). \*Significantly different from (1) control animals; ^\#^significantly different from (4--6) animals treated with neat nanoparticles.\
**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; PDMA, poly(*N*,*N*-dimethylacrylamide).](ijn-12-4257Fig8){#f8-ijn-12-4257}

![In vivo complete blood count of (**A**) white and (**B**) red blood cells in Wistar rats with Walker-256 mammary gland carcinosarcoma. (1) No treatment (control), treatment with (2) 1.5 mg of doxorubicin, (3) 25 mg of Toc-6-Ac, (4) 10 mg of CuFe~2~O~4~, (5) 10 mg of γ-Fe~2~O~3~, (6) 10 mg of γ-Fe~2~O~3~\@PDMA, (7) 10 mg of CuFe~2~O~4~ + 25 mg of Toc-6-Ac, (8) 10 mg of γ-Fe~2~O~3~ + 25 mg of Toc-6-Ac, or (9) 10 mg of γ-Fe~2~O~3~\@PDMA + 25 mg of Toc-6-Ac per kilogram of body weight, and (10) non-treated rats without a tumor (intact control). Data are presented as the mean ± SE (n=5--7). \*Significantly different from (1) control animals.\
**Abbreviation:** PDMA, poly(*N*,*N*-dimethylacrylamide).](ijn-12-4257Fig9){#f9-ijn-12-4257}
